Walgreens Boots Alliance (NASDAQ:WBA) issued an update on its FY19 earnings guidance on Thursday morning. The company provided earnings per share guidance of $6.40-6.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.51. Walgreens Boots Alliance also updated its FY 2019 guidance to $6.44-6.74 EPS.
NASDAQ WBA opened at $67.26 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.38 and a current ratio of 0.80. Walgreens Boots Alliance has a 1 year low of $59.07 and a 1 year high of $86.31. The firm has a market capitalization of $65.84 billion, a P/E ratio of 11.23, a PEG ratio of 1.08 and a beta of 0.76.
Walgreens Boots Alliance (NASDAQ:WBA) last announced its quarterly earnings results on Thursday, December 20th. The pharmacy operator reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.03. The company had revenue of $33.79 billion for the quarter, compared to the consensus estimate of $33.90 billion. Walgreens Boots Alliance had a return on equity of 22.17% and a net margin of 3.96%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $1.28 EPS. On average, analysts expect that Walgreens Boots Alliance will post 6.53 earnings per share for the current fiscal year.
Several equities research analysts have weighed in on the company. Robert W. Baird cut their price target on Walgreens Boots Alliance from $71.00 to $70.00 and set a neutral rating on the stock in a research report on Friday. TheStreet raised Walgreens Boots Alliance from a c+ rating to a b rating in a research report on Wednesday, September 12th. ValuEngine raised Walgreens Boots Alliance from a strong sell rating to a sell rating in a research report on Friday, September 21st. Citigroup increased their price target on Walgreens Boots Alliance from $69.00 to $76.00 and gave the stock a neutral rating in a research report on Friday, October 12th. Finally, Pivotal Research increased their price target on Walgreens Boots Alliance from $60.00 to $72.00 and gave the stock a hold rating in a research report on Monday, October 15th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. Walgreens Boots Alliance currently has a consensus rating of Hold and a consensus target price of $79.39.
In other news, Director Nancy M. Schlichting sold 7,050 shares of the stock in a transaction dated Tuesday, November 20th. The shares were sold at an average price of $78.81, for a total transaction of $555,610.50. Following the sale, the director now directly owns 5,709 shares of the company’s stock, valued at approximately $449,926.29. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Kathleen Wilson-Thompson sold 52,000 shares of the stock in a transaction dated Wednesday, October 31st. The stock was sold at an average price of $78.77, for a total transaction of $4,096,040.00. Following the sale, the executive vice president now directly owns 81,076 shares in the company, valued at $6,386,356.52. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,756 shares of company stock worth $5,824,194. Corporate insiders own 15.73% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Walgreens Boots Alliance (WBA) Updates FY19 Earnings Guidance” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4034924/walgreens-boots-alliance-wba-updates-fy19-earnings-guidance.html.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, beauty, personal care, consumable, and general merchandise products through its retail drugstores and convenient care clinics.
Recommended Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.